歐康維視生物-B(01477.HK):白內障術後炎症藥OT-502在海南獲准用於緊急醫療需求
格隆匯7月7日丨歐康維視生物-B(01477.HK)宣佈,海南省藥品監督管理局已批准集團產品OT-502(DEXYCU®)作為尚未在中國批准用於緊急醫療需求的外國藥品進口至中國海南省博鰲樂城醫療旅遊先行區,其可能加快OT-502在中國的新藥申請提交審批。
OT-502(DEXYCU®)是地塞米松(一種皮質類固醇)的單劑量緩釋溶液,用於治療白內障術後炎症。截至該公吿日期,DEXYCU®是首種也是唯一一種獲美國食品藥品監督管理局批准用於術後炎症的單劑量緩釋型後房內類固醇。集團正在開發OT-502,作為中國白內障手術相關術後炎症的潛在同類首創療法。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.